Paper4136142
Errors in DNA replication as a basis of malignant changes.
Loeb LA and 2 others. Cancer Res, 1974. Cited by 402 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Errors in DNA replication as a basis of malignant changes. Papers, record 4136142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4136142
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA Nucleotidyltransferases | Major topic |
| DNA Replication | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Avian Leukosis Virus | |
| Base Sequence | |
| DNA, Neoplasm | |
| Genotype | |
| Humans | |
| Leukemia | |
| Mutation | |
| Nucleotides | |
| Polynucleotides | |
| RNA-Directed DNA Polymerase | |
| Templates, Genetic |
Source PubMed
Cited by188
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 402 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,738,257 | Selective Inhibition of DNA Polymerase Proofreading: A Metabolic-Fidelity Mechanism Explains Agent Orange-Associated Myelodysplasia. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738257 | PubMed |
| 42,707,399 | Motif-centered analyses reveal universal and tissue-specific mutagenic mechanisms operating in the human body. | NAR Cancer | 2026 | https://conductscience.org/library/papers/42707399 | PubMed |
| 42,042,006 | Selective Inhibition of Proofreading Exonucleases: The Central Role in Obesity-Associated Carcinogenesis. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42042006 | PubMed |
| 42,015,304 | Radiogenomic landscape of the hallmarks of cancer. | Biomark Res | 2026 | https://conductscience.org/library/papers/42015304 | PubMed |
| 41,814,545 | Towards evolutionary guided precision medicine of acute myeloid leukemia and Fanconi anemia associated bone marrow failure. | Stem Cells Transl Med | 2026 | https://conductscience.org/library/papers/41814545 | PubMed |
| 41,756,945 | Motif-Centered Analyses Reveal Universal and Tissue-Specific Mutagenic Mechanisms Operating in the Human Body. | bioRxiv | 2026 | https://conductscience.org/library/papers/41756945 | PubMed |
| 40,610,469 | Personalized cancer treatment strategies incorporating irreversible and reversible drug resistance mechanisms. | NPJ Syst Biol Appl | 2025 | https://conductscience.org/library/papers/40610469 | PubMed |
| 39,273,111 | The Spiral Model of Evolution: Stable Life Forms of Organisms and Unstable Life Forms of Cancers. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39273111 | PubMed |
| 38,231,464 | Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation? | Clin Exp Med | 2024 | https://conductscience.org/library/papers/38231464 | PubMed |
| 38,100,001 | Signification and Application of Mutator and Antimutator Phenotype-Induced Genetic Variations in Evolutionary Adaptation and Cancer Therapeutics. | J Microbiol | 2023 | https://conductscience.org/library/papers/38100001 | PubMed |
| 37,854,902 | DNA mutilation: A telltale sign of cancer inception. | J Oral Maxillofac Pathol | 2023 | https://conductscience.org/library/papers/37854902 | PubMed |
| 37,239,369 | Examining Sporadic Cancer Mutations Uncovers a Set of Genes Involved in Mitochondrial Maintenance. | Genes (Basel) | 2023 | https://conductscience.org/library/papers/37239369 | PubMed |
| 37,122,741 | Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities. | Front Immunol | 2023 | https://conductscience.org/library/papers/37122741 | PubMed |
| 36,781,990 | Survival improvement for patients with metastatic colorectal cancer over twenty years. | NPJ Precis Oncol | 2023 | https://conductscience.org/library/papers/36781990 | PubMed |
| 36,168,102 | Cancer as an infective disease: the role of EVs in tumorigenesis. | Mol Oncol | 2023 | https://conductscience.org/library/papers/36168102 | PubMed |
| 35,850,061 | Extrinsic proofreading. | DNA Repair (Amst) | 2022 | https://conductscience.org/library/papers/35850061 | PubMed |
| 35,326,618 | Polymerase Epsilon-Associated Ultramutagenesis in Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35326618 | PubMed |
| 35,216,513 | The Role of Natural Polymorphic Variants of DNA Polymerase β in DNA Repair. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35216513 | PubMed |
| 35,052,441 | Genome Chaos, Information Creation, and Cancer Emergence: Searching for New Frameworks on the 50th Anniversary of the "War on Cancer". | Genes (Basel) | 2021 | https://conductscience.org/library/papers/35052441 | PubMed |
| 34,944,853 | Therapeutic Targets of KRAS in Colorectal Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944853 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4136142
GET https://conductscience.org/api/papers/v1/4136142/cited_by?page=2